Pet and Livestock Treatment Leader Loses 900 Billion Won in Market Value Overnight

Elanco Animal Health Inc. (NYSE: ELAN), a developer of companion animal and livestock therapies, saw its shares tumble 7.6% on the New York Stock Exchange on the 15th, closing at $20. That sell‐off wiped out roughly $700 million in market value—about 900 billion KRW. Trading volume topped 4.39 million shares, and even after the drop, Elanco’s total market capitalization stands at about $10 billion (approximately 13 trillion KRW).

In its first‐quarter 2026 results released May 6, the company reported revenue of $1.37 billion and adjusted earnings per share of $0.40, both ahead of analysts’ expectations. It also raised its full‐year 2026 revenue and earnings guidance. In late April, Elanco secured emergency‐use authorization from the U.S. Food and Drug Administration and the Environmental Protection Agency for Negasunt Powder and Tanidil to combat New World screwworm in livestock, strengthening its parasiticide portfolio.

Headquartered in Indianapolis, Elanco spun off from Eli Lilly in 2019 and now supplies pharmaceuticals and vaccines for pets and farm animals worldwide. With blockbuster new products such as Credelio Quattro, Zenrelia and Befrena, coupled with ongoing restructuring, the company is targeting mid‐single‐digit revenue growth and near‐double‐digit profit growth—an outlook that supports its medium‐ to long‐term growth story despite the recent share price decline.